Novel Cancer Vaccine Combined With Pembrolizumab Shows Promise in Metastatic Melanoma

Source: Targeted Oncology, August 2021

Combination treatment with the universal cancer vaccine, UV1, and the immune checkpoint inhibitor, pembrolizumab (Keytruda) showed strong signals of clinical response in patients with metastatic melanoma while also meeting its key safety/tolerability end point, according to findings announced in a press release by Ultimovacs ASA.1

READ THE ORIGINAL FULL ARTICLE
Menu